In India, Pfizer operates three manufacturing plants and works with 18 other partner sites to produce quality medicines for patients in India. All manufacturing operations are carried out in full compliance with local laws and in line with stringent Global Pfizer Quality and environment, health and safety (EHS) standards.
I. Goa, India
An award-winning facility that manufactures small molecule drugs and local solids
Year of establishment: 2001
No. of colleagues: ~150
Capacity: 4 billion tablets annually
Markets supplied: India, Bangladesh, Sri Lanka, Nepal
II. Visakhapatnam, India
One of Pfizer’s largest modern facilities in the world for sterile injectables
Year of establishment: 2015
No. of colleagues: ~2000
Capacity: 380 million vials annually
Markets supplied: United States, Canada (filings in progress)
III. Ahmedabad, India
The Zydus Hospira Oncology Pvt. Ltd. (ZHOPL) plant is a 50:50 joint venture with Zydus Cadila that manufactures sterile injectables.
Year of establishment: 2005
No. of colleagues: ~150
Capacity: 7 million vials annually
Markets supplied: US, Europe, Australia and New Zealand, Japan, Canada, Asia Pacific
Sustainability
Pfizer puts a strong emphasis on conservation of resources at our manufacturing sites. Our Goa plant has received a number of awards including one for Excellence in Environment Sustainability because of its emphasis on global safety, environmental health and hygiene standards. We have also replaced several old manufacturing machines and dehumidifiers with high-efficiency machines to reduce energy consumption.
At Vishakhapatnam, our plant runs exhaustive sustainability programs on all three areas of sustainability (Water, Energy and Waste). The site has met all sustainability targets over the years and has been recognized by reputed organizations.
Training
We conduct several training programmes through the year to motivate colleagues and encourage best practices. We arrange the Integrated Manufacturing Excellence Program (IMEx) for leaders and the Six Sigma Green Belt training and Operational Excellence trainings.
Special measures during Covid-19
During the Covid-19 pandemic, it was clear to us that we needed to ensure an uninterrupted supply of medicines without any disruption, while also taking care of the health and safety of our employees. We took all the necessary steps to make certain that there was no disruption to supply during this time and ensured that the health and safety of our employees remained a top priority. Our plants were classified as an ‘essential service’ and remained operational through the lockdowns. All colleagues maintained social distance during operations, were screened for their temperature, were provided masks and sanitization dispensers on site.Insert your text here